Sanofi: positive results for Sutimlimab

(CercleFinance.com) - On Tuesday Sanofi announces that Sutimlimab, its new experimental C1s complement inhibitor, may become the first drug approved for the treatment of cold agglutinin disease, a rare, chronic and serious blood disorder.


A phase 3 trial has met its primary and secondary endpoints, and its results show rapid inhibition of hemolysis, as well as clinically significant improvements in anemia and fatigue after one week of treatment, Sanofi says.

The group says that it plans to submit its inhibitor to the US FDA "in the near future".


Copyright (c) 2019 CercleFinance.com. All rights reserved.